Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis

Background: To verify the accuracy of serum dickkopf-1 protein (DKK-1) in the diagnosis of hepatocellular carcinoma (HCC) by an updated meta-analysis. Methods: We searched potential eligible studies in PubMed and Embase before July 8, 2018. Sensitivity (SN), specificity (SP), positive likelihood ratio (PLR), negative likelihood ratio (NLR), summary receiver operating characteristics curve (sROC), and diagnostic odds ratio (DOR) were pooled with their 95% confidence intervals CIs) using a bivariate random-effects model. Results: A total of 8 articles contained 10 studies on diagnosis of HCC with DKK-1 alone,7 articles contained 9 studies on diagnosis of HCC with a-fetoprotein (AFP) alone and 5 articles contained 7 studies on diagnosis of HCC with DKK-1 + AFP were identified. The pooled SN, SP, PLR, NLR, and DOR of DKK-1 alone, AFP alone and DKK-1 + AFP were 0.72 (95% CI: 0.70–0.75), 0.62 (95% CI:0.59–0.64) and 0.80 (95% CI:0.78–0.83), 0.86 (95% CI: 0.84–0.87), 0.82 (95% CI:0.80–0.84) and 0.87 (95% CI: 0.85–0.88), 4.91 (95% CI: 2.73–8.83), 3.60 (95% CI:2.01–6.44) and 6.18 (95% CI: 4.68–8.16), 0.32 (95% CI: 0.22–0.47), 0.49 (95% CI:0.40–0.60) and 0.20 (95% CI: 0.15–0.26), and 17.21 (95% CI: 9.10–32.57), 7.45 (95% CI:3.69–15.01) and 31.39 (95% CI: 23.59–43.20), respectively. The area under the sROC was 0.88, 0.70, and 0.92 for the 3 diagnostic methods. Conclusions: Serum DKK-1 + AFP showed a high accuracy for diagnosis of HCC, and serum DKK-1 alone had moderate accuracy as compared to a previous meta-analysis, while AFP alone owned an unsatisfied diagnostic behavior for HCC. Due to the limitations of the current analysis, further well-designed studies are needed to confirm the diagnostic value of DKK-1 and DKK-1 + AFP in HCC diagnosis.

show abstract

“…However, with AUC of 0.92, the combination of DKK-1 and AFP showed an equivalent diagnostic performance as compared to OPN and DCP. [46,47]…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of serum dickkopf-1 protein in diagnosis hepatocellular carcinoma

Mou

Gao

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…When osteopontin was combined with AFP, the AUC was even higher for early-stage HCC patients (AUC: 0.81 [95% CI: 0.70-0.91]). In a recent meta-analysis, a combination of osteopontin and AFP resulted future science group www.futuremedicine.com in a sensitivity of 82% and specificity of 77% for HCC detection, although the overall proportion of patients included with early-stage disease was small [38].…”

Section: • • Phase III Biomarkers Longitudinal Testing Of Retrospectimentioning

confidence: 99%

Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

Sengupta

Parikh

2017

Hepat. Oncol.

View full text Add to dashboard Cite

Early detection of hepatocellular carcinoma (HCC) leads to improved survival; however, current early detection strategies for HCC surveillance are ineffective. Thus, there has been interest in developing biomarkers to aid in the early detection HCC. In this review, we discuss the five phases of biomarker discovery that are necessary for clinical implementation. We also describe the most promising investigational biomarkers and their phase of discovery. We review several promising technologies for the early detection of HCC, including miRNA, metabolomics and proteomics. Promisingly, there are samples from multiple longitudinal cohorts of patients with cirrhosis in the USA that are being collected in order to validate candidate biomarkers for HCC. A biomarker-based strategy has the potential to become the primary surveillance method for HCC detection.

show abstract

“…In a meta-analysis investigating the efficacy of OPN in HCC detection, the sensitivity and specificity of elevated OPN levels have been reported between 75%-87% and 62%-82%, respectively [62] . The combined utilization of AFP and OPN resulted in a sensitivity of 82% and specificity of 77% for HCC detection; however, the number of patients at BCLC stage 0/A was limited in this study [63] .…”

Section: Osteopontinmentioning

confidence: 84%

Evaluation and impact of different biomarkers for early detection of hepatocellular carcinoma

Best¹,

Sydor²,

Bechmann³

et al. 2020

View full text Add to dashboard Cite

Worldwide, hepatocellular carcinoma (HCC) is a frequent complication of liver diseases and remains a major cause of cancer-related mortality. In addition, the prevalence of nonalcoholic steatohepatitis (NASH) as prerequisite of hepatocarcinogenesis, even in the absence of cirrhosis, is rising rapidly. The early detection of HCC has been crucial in improving the survival outcomes of those patients. However, in the mostly obese NASH population, diagnostic sensitivity of ultrasound-based HCC screening approaches is limited. On the other hand, biomarkers for HCC show promising potential to improve early detection, providing reproducible, investigator-independent results that can be used either alone or integrated with other biomarkers for scoring models. In the past, validation has been limited due to a lack of prospective longitudinal cohort studies. At present, large-scale retrospective phase-III-biomarker-development gives hope for the availability of biomarker-based screening approaches in the near future. This review focuses on the potential impact of biomarkers on surveillance strategies, potentially allowing for earlier HCC diagnosis.

show abstract

Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis

Cited by 11 publications

References 42 publications

Diagnostic accuracy of serum dickkopf-1 protein in diagnosis hepatocellular carcinoma

Diagnostic accuracy of serum dickkopf-1 protein in diagnosis hepatocellular carcinoma

Biomarker development for hepatocellular carcinoma early detection: current and future perspectives

Evaluation and impact of different biomarkers for early detection of hepatocellular carcinoma

Contact Info

Product

Resources

About